Elsevier

Archives of Gerontology and Geriatrics

Volume 11, Issue 3, November–December 1990, Pages 177-186
Archives of Gerontology and Geriatrics

Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review

https://doi.org/10.1016/0167-4943(90)90063-CGet rights and content

Abstract

The name idebenone (CV-2619) was given to a synthetic compound the chemical structure of which is 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (commercial name in Japan: Avan). Although it is insoluble in water, suspensions of it can be applied and are absorbed relatively well from the intestine. Its acute toxicity is very low, and is well tolerated also in subacute and chronic treatments. It displayed no immunogenic or mutagenic side effects in the models studied so far. Pharmacological studies of idebenone revealed that (i) it acts as a free radical scavenger and protects the mitochondrial membrane against lipid peroxidation; (ii) it prevents platelet aggregation; (iii) it improves vascular disorders due to strokes or experimental cerebral ischemia; (iv) it recovers the cholinergic and monoaminergic changes in the ischemic brain; (v) it improves overall brain function (including memory, also) in various animal models. Pharmacokinetic studies have confirmed that it reaches the brain cells even after per os administration. The main conclusion from the experimental data was that idebenone may be of beneficial effect for the neurological disorders related to cerebral ischemia even in humans: the results obtained so far in human clinical trials confirmed the validity of this expectation for cases of human cerebrovascular disease.

References (72)

  • A. Nagaoka et al.

    Inhibitory effect of idebenone (CV-2619), a novel compound, on vascular leasions in hypertensive rats

    Jpn. J. Pharmacol.

    (1984)
  • A. Nagaoka et al.

    Effects of idebenone on neurological deficits, local cerebral blood flow, and energy metabolism in rats with experimental cerebral ischemia

    Arch. Gerontol. Geriatr.

    (1989)
  • A. Nagaoka et al.

    Effects of idebenone on neurological deficits following cerebrovascular lesions in stroke-prone spontaneously hypertensive rats

    Arch. Gerontol. Geriatr.

    (1989)
  • T. Nakano et al.

    Effects of idebenone on electroencephalograms of patients with cerebrovascular disorders

    Arch. Gerontol. Geriatr.

    (1989)
  • S. Narumi et al.

    Effects of idebenone (CV-2619) on the metabolism of monoamines especially serotonin, in the brain of normal rats and rats with cerebral ischemia

    Jpn. J. Pharmacol.

    (1985)
  • Y. Sugiyama et al.

    Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism

    FEBS Lett.

    (1985)
  • M. Suno et al.

    Inhibition of lipid peroxidation by a novel compound, idebenone (CV-2619)

    Jpn. J. Pharmacol.

    (1984)
  • M. Suno et al.

    Inhibition of lipid peroxidation by a novel compound, idebenone (CV-2619) in brain mitochondria and mode of action of the inhibition

    Biochem. Biophys. Res. Commun.

    (1984)
  • M. Suno et al.

    Inhibition of lipid peroxidation by idebenone in brain mitochondria in the presence of succinate

    Arch. Gerontol. Geriatr.

    (1989)
  • M. Suno et al.

    Inhibition of brain mitochondrial swelling by idebenone

    Arch. Gerontol. Geriatr.

    (1989)
  • M. Suno et al.

    Effects of idebenone on lipid peroxidation and hemolysis in erythrocytes of stroke-prone spontaneously hypertensive rats

    Arch. Gerontol. Geriatr.

    (1989)
  • M. Suno et al.

    Inhibition of platelet aggregation by idebenone and the mechanism of the inhibition

    Arch. Gerontol. Geriatr.

    (1989)
  • M. Takada et al.

    Simultaneous determination of reduced and oxidized ubiquinones

    Methods Enzymol.

    (1984)
  • N. Yamazaki et al.

    Beneficial effect of idebenone (CV-2619) on cerebral ischemia-induced amnesia in rats

    Jpn. J. Pharmacol.

    (1984)
  • N. Yamazaki et al.

    Effects of idebenone on memory impairment induced in ischemic and embolization models of cerebrovascular disturbance in rats

    Arch. Gerontol. Geriatr.

    (1989)
  • N. Yamazaki et al.

    Idebenone improves learning and memory impairment induced by cholinergic or serotonergic dysfunction in rats

    Arch. Gerontol. Geriatr.

    (1989)
  • M. Arakawa et al.

    Immunogenicity studies on idebenone (CV-2619)

    Jpn. Pharmacol. Ther.

    (1985)
  • S. Chiba et al.

    Acute toxicity study of idebenone (CV-2619) in mice and rats

    Jpn. Pharmacol. Ther.

    (1985)
  • G. Doná et al.

    A double-blind study of the efficacy of Idebenone in the treatment of patients with cognitive deficit due to cerebrovascular disease

    Acta Gerontol. (Pavia)

    (1988)
  • S. Ichimaru

    Efficacy and safety CV-2619 tablets in long-term clinical treatment of elderly cerebral arteriosclerotic patients

    Rinsho Iyaku

    (1985)
  • T. Ihara et al.

    Effects of idebenone (CV-2619) on fertility and general reproductive performance in the rat

    Jpn. Pharmacol. Ther.

    (1985)
  • T. Ihara et al.

    Effects of idebenone (CV-2619) on peri- and post-natal development in the rat

    Jpn. Pharmacol. Ther.

    (1985)
  • T. Ihara et al.

    Teratogenic effects of idebenone (CV-2619) in the rat

    Jpn. Pharmacol. Ther.

    (1985)
  • T. Ihara et al.

    Teratogenic effects of idebenone (CV-2619) in the rabbit

    Jpn. Pharmacol. Ther.

    (1985)
  • M. Kakihana et al.

    Changes of behavior, cerebral blood flow and metabolism after bilateral carotid occlusion in stroke-prone SHR, Stroke-resistant SHR and normal Wistar-Kyoto rats

    Jpn. Heart J.

    (1980)
  • Y. Kiyota et al.

    Combination effects of Idebenone and Vinpocetine on N2-induced hypoxia and CO2-induced amnesia in mice

    Jpn. Pharmacol. Ther.

    (1987)
  • Cited by (78)

    • Rational design, synthesis and biological evaluation of ubiquinone derivatives as IDO1 inhibitors

      2019, Bioorganic Chemistry
      Citation Excerpt :

      There are many approved drugs or diet supplement containing the quinone scaffold, such as Idebenone and coenzyme Q10 (CoQ10). Idebenone and CoQ10 share the same p-quinone headgroup (CoQ0) and both of them are treated as a drug or dietary supplement in many countries [36–43]. CoQ10 is a main homologue of CoQ existing in humans, and Idebenone, a synthetic quinone with similarities to coenzyme-Q1, had been introduced to the market in 1986 under the name Avan in Japan [36–43].

    • Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition

      2018, Pharmacological Research
      Citation Excerpt :

      Idebenone is approved in Europe for treatment of visual impairment due to Leber's hereditary Optic Neuropathy, LHON [76–85], and has been considered for Duchenne's Muscular Dystrophy, DMD [86–89]. It is possible that idebenone's efficacy in LHON and DMD may be supported by the Shc mechanism rather than or in addition to its mitochondrial mechanisms previously described, especially as idebenone engages the Shc target at the 100 nM plasma concentrations reached by idebenone in human patients [64–66]. HTS for metabolic insulin sensitizers, validation of compounds, mitochondrial IC50 determination, EC50 of insulin sensitization, identification of idebenone as a Shc inhibitor/insulin sensitizer – Tomilov; Affinity of 30 identified compounds to Shc protein Allen; IC50 of Shc-NPEYp interaction for 7 identified compounds, establishment of NPEYp binding assays and Shc – Chun Kiu; Blinded measurement of insulin sensitivity in vivo – Bettaieb; overseeing entire project – Cortopassi.

    • Cellular interactions and photoprotective effects of idebenone-loaded nanostructured lipid carriers stabilized using PEG-free surfactant

      2015, International Journal of Pharmaceutics
      Citation Excerpt :

      It is well known that excessive production of ROS or reduction in the endogenous antioxidants to neutralize them results in oxidative stress which in turn causes damage to intracellular lipids, proteins and DNA (Linder, 2010). IDB, a key cell membrane antioxidant and essential constituent of electron transport chain (ETC) in mitochondria, acts by inhibiting the lipid peroxidation and thus protects cell membrane and mitochondria membrane integrity from oxidative stress (Suno and Nagaoka, 1984; Zs-Nagy, 1990). Regarding the placebo-NLCs + UVB (Fig. 10A), it is seen that it exhibited significantly lower MFI, when compared to positive control cells (p < 0.001), indicating the placebo-NLCs under UVB irradiation provided photoprotection but they in spite of that compromised over 3-fold increase in ROS production, when compared to IDB–NLCs + UVB, indicating loading of IDB in NLCs system boosted HaCaT cell’s protection against oxidative stress.

    • Evolution of cytochrome bc complexes: From membrane-anchored dehydrogenases of ancient bacteria to triggers of apoptosis in vertebrates

      2013, Biochimica et Biophysica Acta - Bioenergetics
      Citation Excerpt :

      Propofol treatment had strong dose-dependent protection attenuating alteration of these parameters [204]. An ubiquinone analog idebenone (6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone) has been shown to protect the mitochondrial membrane against lipid peroxidation and improve the overall brain function after vascular disorders due to strokes or experimental cerebral ischemia [205–208]. Another ubiquinol analog, decylubiquinol, also blocked ROS production and prevented activation of the mitochondrial permeability transition and the cell death [209].

    View all citing articles on Scopus
    View full text